| pubmed-article:11177406 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:11177406 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:11177406 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11177406 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11177406 | pubmed:abstractText | IL-12 production is reduced in HIV infection, and recombinant human IL-12 (rhIL-12) augments in vitro HIV-specific proliferative responses in PBMC from HIV-seropositive individuals. To determine whether rhIL12 could also augment HIV-specific CTL responses we studied 41 HIV-seropositive individuals. Recombinant hIL-12 increased the detectable in vitro HIV-specific CD8 CTL activity of PBMC taken from HIV-seropositive individuals with CD4 counts >500 cells/microl and from some individuals with lower CD4 counts. IL-12 increased cell recovery in cultures of PBMC from HIV-seropositive individuals with CD4 counts >500 cells/microl and also increased the precursor CTL frequency. However, the increase in HIV-specific CTL activity was not due to IL-2 or IFN-gamma production or an increase in the number of cells with surface markers characteristic of CTL effector cells. This study demonstrates that rhIL-12 augments in vitro HIV-specific CTL activity and provides evidence to justify further investigation within clinical trials of this cytokine in HIV infection. | lld:pubmed |
| pubmed-article:11177406 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11177406 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11177406 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11177406 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11177406 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11177406 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11177406 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11177406 | pubmed:issn | 0889-2229 | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:YoungJ MJM | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:StewartG JGJ | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:LiangTT | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:PackhamDD | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:BensonE MEM | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:FulcherD ADA | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:FfrenchR ARA | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:ClarksonJ DJD | lld:pubmed |
| pubmed-article:11177406 | pubmed:author | pubmed-author:TidemanR LRL | lld:pubmed |
| pubmed-article:11177406 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11177406 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:11177406 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:11177406 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11177406 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11177406 | pubmed:pagination | 233-42 | lld:pubmed |
| pubmed-article:11177406 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:meshHeading | pubmed-meshheading:11177406... | lld:pubmed |
| pubmed-article:11177406 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11177406 | pubmed:articleTitle | In vitro HIV-specific CTL activity from HIV-seropositive individuals is augmented by interleukin-12 (IL-12). | lld:pubmed |
| pubmed-article:11177406 | pubmed:affiliation | Department of Immunology, Westmead Hospital, Westmead, NSW 2145, Australia. jyou5571@mail.usyd.edu.au | lld:pubmed |
| pubmed-article:11177406 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11177406 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11177406 | lld:pubmed |
